NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

“Study May Proceed” letter received from FDA IND preclinical requirements are consistent with studies already in progress to support treatment of Bipolar Depression Potential to initiate registrational studies in 2024, pending receipt of data from already-completed DOD-funded trial of…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.